Drug Development
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
As the spread of the Delta variant exacerbates the COVID-19 pandemic, companies are increasingly moving toward requiring staffers to be vaccinated. Here’s a look at those stories and more.
The announcement for the chikungunya vaccine (VLA1553) comes after the U.S. FDA awarded it with a Breakthrough Designation status. Read more about it here.
Pfizer said that the Phase IIb/III ALLEGRO trial on ritlecitinib was found to be effective against the autoimmune disease, which is characterized by an immune attack on hair follicles.
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
The FDA-initiated partial hold on Novartis’ gene therapy trial for spinal muscular atrophy has been lifted recently. Here’s everything you need to know about it.
Sage announced the termination of the REDWOOD and RAINFOREST studies of zuranolone, which is being assessed to treat both major depressive disorder and post-partum depression.
Shares in the company climbed more than 30% premarket following the news of the study findings. The major reason is believed to be the performance of bevacizumab.
Eli Lilly and Company is in the news with positive Olumiant data in COVID-19, a drop in COVID-19 product sales for the quarter and a protest of one of their ads. Here’s a look.
The company announced that it is withdrawing its peripheral T-cell lymphoma drug Istodax from the market after recent trials showed that it does not achieve its primary efficacy endpoint.
Late-phase trial data show Servier’s TIBSOVO, in conjunction with chemotherapy azacitidine, prolonged event-free survival in adult patients with previously untreated IDH1-mutated acute myeloid leukemia.